Tumor necrosis factor-α in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5310-5317

  Saw, Valerie P J ^a,b   Dart, Robin J C ^a   Galatowicz, Grazyna ^a   Daniels, Julie T ^a   Dart, John K G ^a,b   Calder, Virginia L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; B7 ANTIGEN; BETAXOLOL; BIMATOPROST; BRIMONIDINE; CARBOMER; CARBOMER 980; CARBOXYMETHYLCELLULOSE; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; COLLAGEN; CYCLOPENTOLATE; DAPSONE; DEXAMETHASONE; DORZOLAMIDE; GELATINASE B; HLA DR ANTIGEN; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; INTERCELLULAR ADHESION MOLECULE 1; LATANOPROST; LIQUID PARAFFIN; MATRIX METALLOPROTEINASE; MYCOPHENOLIC ACID; PREDNISOLONE; TIMOLOL; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGED; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; COLLAGEN METABOLISM; CONJUNCTIVA; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; OCULAR MUCOUS MEMBRANE PEMPHIGOID; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SCHOOL CHILD; STROMA CELL; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL ADHESION MOLECULES; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; CONJUNCTIVA; FEMALE; FIBROBLASTS; HLA-DR ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72249110288     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3345     Document Type: Article

References (42)

1. Oyama N, Setterfield JF, Powell AM. Bullous pemphigoid antigen ii (bp180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol. 2006; 154(1):90-98.
2. Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115:253-261.
3. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142(11):1457-1461.
4. John H, Whallett A, Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye. 2007;21(11):1434-1435.
5. Prey S, Robert PY, Drouet M, et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol. 2007;87(1):74-75.
6. Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1993;34(13):3522-3525.
7. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pre-treatment TNFα expression in the synovium. Ann Rheum Dis. 2008;67(8):1139-1144.
8. Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008;6(3):128-142.
9. Razzaque MS, Foster CS, Ahmed AR. Tissue and molecular events in human conjunctival scarring in ocular cicatricial pemphigoid. Histol Histopathol. 2001;16(4):1203-1212.
10. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210.
11. Stramer BM, Mori R, Martin P. The inflammation-fibrosis link?-a Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol. 2007;127(5):1009-1017.
12. Kaufman J, Graf BA, Leung EC, et al. Fibroblasts as sentinel cells: role of the CDcd40-CDcd40 ligand system in fibroblast activation and lung inflammation and fibrosis. Chest. 2001;120(1 suppl):53S-55S.
13. Sempowski GD, Chess PR, Phipps RP. CD40 is a functional activation antigen and b7-independent T cell costimulatory molecule on normal human lung fibroblasts. J Immunol. 1997;158(10): 4670-7.
14. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol. 2008;153(suppl 1):S241-S246.
15. Miserocchi E, Baltatzis S, Roque MR, Ahmed AR, Foster CS. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002; 109(1):111-118.
16. Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum. 2008;58(8):2228-2235.
17. Saika S, Ikeda K, Yamanaka O, et al. Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing. Am J Pathol. 2006; 168(6):1848-1860.
18. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factoralpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol. 2005;32(4):342-349.
19. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005; 280(43):36099-36109.
20. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol. 2007;34(7):1636-1637.
21. Bernauer W, Wright P, Dart JK, Leonard JN, Lightman S. The conjunctiva in acute and chronic mucous membrane pemphigoid: an immunohistochemical analysis. Ophthalmology. 1993;100(3): 339-346.
22. Khaw PT, Ward S, Porter A, Grierson I, Hitchings RA, Rice NS. The long-term effects of 5-fluorouracil and sodium butyrate on human tenon's fibroblasts. Invest Ophthalmol Vis Sci. 1992;33(6):2043-2052.
23. Leonardi A, Cortivo R, Fregona I, Plebani M, Secchi AG, Abatangelo G. Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2003;44(1):183-189.
24. Mazure A, Grierson I. In vitro studies of the contractility of cell types involved in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33(12):3407-3416.
25. Rice BA, Foster CS. Immunopathology of cicatricial pemphigoid affecting the conjunctiva. Ophthalmology. 1990;97(11):1476-1483.
26. Sacks EH, Jakobiec FA, Wieczorek R, Donnenfeld E, Perry H, Knowles DM Jr. Immunophenotypic analysis of the inflammatory infiltrate in ocular cicatricial pemphigoid: further evidence for a T cell-mediated disease. Ophthalmology. 1989;96(2):236-243.
27. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis. 2007;66(suppl 3):iii2-iii22.
28. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res. 2004;64(3):507-515.
29. Elder MJ. The role of cytokines in chronic progressive conjunctival cicatrisation. Dev Ophthalmol. 1997;28:159-175.
30. Razzaque MS, Ahmed BS, Foster CS, Ahmed AR. Effects of IL-4 on conjunctival fibroblasts: possible role in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 2003;44(8):3417-3423.
31. Cordero CM, Yilmaz T, Foster CS. Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid. Acta Ophthalmol Scand. 2007;85(7):753-755.
32. Bernauer W, Wright P, Dart JK, Leonard JN, Lightman S. Cytokines in the conjunctiva of acute and chronic mucous membrane pemphigoid: an immunohistochemical analysis. Graefes Arch Clin Exp Ophthalmol. 1993;231(10):563-570.
33. Razzaque MS, Foster CS, Ahmed AR. Role of Enhanced expression of M-CSF in conjunctiva affected by cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 2002;43(9):2977-2983.
34. Razzaque MS, Foster CS, Ahmed AR. Role of macrophage migration inhibitory factor in conjunctival pathology in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 2004;45(4):1174-1181.
35. Roat MI, Sossi G, Lo CY, Thoft RA. Hyperproliferation of conjunctival fibroblasts from patients with cicatricial pemphigoid. Arch Ophthalmol. 1989;107:1064-1067.
36. Chen Y, Shi-wen X, Eastwood M, et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 2006;54(4):1309-1316.
37. Daniels JT, Cambrey AD, Occleston NL, et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest Ophthalmol Vis Sci. 2003;44(3):1104-1110.
38. Kim SJ, Chung YK, Chung TW, Kim JR, Kim CH, Park YG. Regulation of matrix metalloproteinase-9 expression between gingival fibroblast cells from old and young rats. Biochem Biophys Res Commun. 2009;378(2):152-156.
39. Dufour A, Sampson NS, Zucker S, Cao J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol. 2008;217(3):643-651.
40. Stetler-Stevenson WG, Seo DW. TIMP-2: an Endogenous inhibitor of angiogenesis. Trends Mol Med. 2005;11(3):97-103.
41. Wong TT, Sethi C, Daniels JT, Limb GA, Murphy G, Khaw PT. Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol. 2002;47(3):239-256.
42. Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea. 1992;11(5): 446-451.